Next 10 |
Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatment for non-muscle invasive bladder cancer (NMIBC) Serum Institute of India (SII) will manufacture both standard BCG (“sBCG”) and n...
Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program “A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC” Discussion about the basis for ANKTIVA’s Breakthrough Therapy designation and the novel mechanism o...
2024-04-29 11:26:05 ET ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva , its cancer drug. It has risen for two straight days and is now sitting at its highest level since September 2021. It is up by over 770% from its l...
2024-04-29 10:02:54 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
A look at the top 10 most actives in the United States SoFi Technologies Inc. (SOFI) fell 9.7% to $7.1068 on volume of 45,729,887 shares Tesla Inc. (TSLA) rose 11.6% to $187.7701 on volume of 45,057,076 shares Collective Audience Inc. (CAUD) rose 71.6% to $0.669199 on volume of 34,955,653...
2024-04-29 08:36:50 ET More on premarket gainers & stock Diving Into Deciphera Pharmaceuticals Fulton Financial Corporation (FULT) Q1 2024 Earnings Call Transcript Fulton Financial Corporation 2024 Q1 - Results - Earnings Call Presentation Fulton Financia...
A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 20.6% to $0.0626 on volume of 316,091,551 shares Snap Inc. Class A (SNAP) rose 27.6% to $14.55 on volume of 158,621,648 shares PROSHARES TRUST (SQQQ) fell 4.8% to $11.43 on volume of 135,432,504 share...
2024-04-25 07:44:32 ET Shares of ImmunityBio ( NASDAQ: IBRX ) rose as much as 17% premarket on Thursday after the biotech reported positive overall survival results from a trial evaluating its immunotherapy drug, Anktiva, in non-small cell lung cancer (NSCLC).... Read the ...
QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2 nd - and 3 rd -line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy Positive results se...
2024-04-23 17:11:27 ET Summary San Diego-based biotech company ImmunityBio has received its first US drug approval for its lead drug candidate Anktiva, an immunotherapy for bladder cancer. Anktiva received Breakthrough Therapy Designation and approval from the FDA based on its saf...
News, Short Squeeze, Breakout and More Instantly...
ImmunityBio Inc. Company Name:
IBRX Stock Symbol:
NASDAQ Market:
U.S. stocks were higher, with the Dow Jones index gaining over 400 points on Friday. Shares of Amgen Inc. (NASDAQ:AMGN) rose sharply during Friday&...
Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatment for non-muscle invasive bladder cancer (NMIBC) Serum Institute of India (SII) will manufacture both standard BCG (“sBCG”) and n...
Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program “A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC” Discussion about the basis for ANKTIVA’s Breakthrough Therapy designation and the novel mechanism o...